Search research articles
Contact Us
Filters
Showing results (41-50 of 120) with videos related to
Page
of 12
Sort By:
European Heart Journal
|
August 14, 2023
Glycerol and β-hydroxybutyrate: friends or foes?
Lale Tokgözoğlu, Angela Pirillo, Alberico Luigi Catapano
European Heart Journal
|
November 8, 2024
Can apoA-I infusion decrease cardiovascular events?
Lale Tokgözoğlu, Angela Pirillo, Alberico L Catapano
Pharmacological Research
|
September 22, 2023
European guidelines for the treatment of dyslipidaemias: New concepts and future challenges
Angela Pirillo, Manuela Casula, Alberico L Catapano
European Journal of Preventive Cardiology
|
April 15, 2025
Apolipoprotein C3 and cardiovascular risk: New insights from the ODYSSEY Outcomes trial
Alberico Luigi Catapano, Angela Pirillo, Lale Tokgözoğlu
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|
July 11, 2006
Modified HDL: biological and physiopathological consequences
Giuseppe Danilo Norata, Angela Pirillo, Alberico Luigi Catapano
Current Opinion in Lipidology
|
September 2, 2011
HDLs, immunity, and atherosclerosis
Giuseppe D Norata, Angela Pirillo, Alberico L Catapano
Cardiology
|
February 23, 2013
High-density lipoprotein subfractions--what the clinicians need to know
Angela Pirillo, Giuseppe Danilo Norata, Alberico Luigi Catapano
Clinical Chemistry
|
November 25, 2020
Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years
Angela Pirillo, Giuseppe Danilo Norata, Alberico L Catapano
Current Pharmaceutical Design
|
January 5, 2013
Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality
Angela Pirillo, Giuseppe Danilo Norata, Alberico Luigi Catapano
Handbook of Experimental Pharmacology
|
May 1, 2020
LDL-Cholesterol-Lowering Therapy
Angela Pirillo, Giuseppe D Norata, Alberico L Catapano
Page
of 12
Search research articles
Search
Showing results (41-50 of 120) with videos related to
Sort By:
Page
of 12
European Heart Journal
|
August 14, 2023
Glycerol and β-hydroxybutyrate: friends or foes?
Lale Tokgözoğlu, Angela Pirillo, Alberico Luigi Catapano
European Heart Journal
|
November 8, 2024
Can apoA-I infusion decrease cardiovascular events?
Lale Tokgözoğlu, Angela Pirillo, Alberico L Catapano
Pharmacological Research
|
September 22, 2023
European guidelines for the treatment of dyslipidaemias: New concepts and future challenges
Angela Pirillo, Manuela Casula, Alberico L Catapano
European Journal of Preventive Cardiology
|
April 15, 2025
Apolipoprotein C3 and cardiovascular risk: New insights from the ODYSSEY Outcomes trial
Alberico Luigi Catapano, Angela Pirillo, Lale Tokgözoğlu
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|
July 11, 2006
Modified HDL: biological and physiopathological consequences
Giuseppe Danilo Norata, Angela Pirillo, Alberico Luigi Catapano
Current Opinion in Lipidology
|
September 2, 2011
HDLs, immunity, and atherosclerosis
Giuseppe D Norata, Angela Pirillo, Alberico L Catapano
Cardiology
|
February 23, 2013
High-density lipoprotein subfractions--what the clinicians need to know
Angela Pirillo, Giuseppe Danilo Norata, Alberico Luigi Catapano
Clinical Chemistry
|
November 25, 2020
Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years
Angela Pirillo, Giuseppe Danilo Norata, Alberico L Catapano
Current Pharmaceutical Design
|
January 5, 2013
Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality
Angela Pirillo, Giuseppe Danilo Norata, Alberico Luigi Catapano
Handbook of Experimental Pharmacology
|
May 1, 2020
LDL-Cholesterol-Lowering Therapy
Angela Pirillo, Giuseppe D Norata, Alberico L Catapano
Page
of 12